Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Swixx BioPharma","sponsor":"Amryt Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Amryt and Swixx Sign Distribution Deal for Lojuxta","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"October 2020","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Swixx BioPharma","sponsor":"Y-mAbs Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Y-mAbs Signs Distribution Agreement with Swixx for DANYELZA\u00ae and Omburtamab in Eastern Europe","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Approved","date":"December 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Approved"},{"orgOrder":0,"company":"Swixx BioPharma","sponsor":"BioCryst Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BioCryst Selects Swixx BioPharma as Commercial Partner for ORLADEYO\u00ae (berotralstat) in Central and Eastern Europe","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"January 2023","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals by Swixx BioPharma

    Menu

    Swixx BioPharma

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Swixx BioPharma

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Switzerland
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              BioCryst Selects Swixx BioPharma as Commercial Partner for ORLADEYO® (berotralstat) in Central and Eastern Europe

              Details:

              Under the terms of the agreement, Swixx will be responsible for commercializing ORLADEYO in 15 markets within CEE. Orladeyo (berotralstat) is the first and only oral therapy designed specifically to prevent attacks of HAE in adult and pediatric patients 12 years and older.

              Lead Product(s): Berotralstat

              Therapeutic Area: Genetic Disease Product Name: Orladeyo

              Highest Development Status: Approved Product Type: Small molecule

              Recipient: BioCryst Pharmaceuticals

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration January 23, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Swixx BioPharma

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Switzerland
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Y-mAbs Signs Distribution Agreement with Swixx for DANYELZA® and Omburtamab in Eastern Europe

              Details:

              Swixx BioPharma will exclusively distribute DANYELZA to treat patients with relapsed/refractory high-risk neuroblastoma and omburtamab, if approved, for pediatric patients with CNS/leptomeningeal metastasis from neuroblastoma in Eastern Europe, including Russia.

              Lead Product(s): Naxitamab,Granulocyte-macrophage colony-stimulating factor

              Therapeutic Area: Oncology Product Name: DANYELZA

              Highest Development Status: Approved Product Type: Large molecule

              Recipient: Y-mAbs Therapeutics

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement December 18, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Swixx BioPharma

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Switzerland
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Amryt and Swixx Sign Distribution Deal for Lojuxta

              Details:

              Under the agreement, Swixx will distribute Lojuxta® from October 2020 in Albania, Bosnia and Herzegovina, Bulgaria, Croatia, Estonia, Kosovo, Latvia, Lithuania, Montenegro, North Macedonia, Poland, Romania, Serbia and Slovakia.

              Lead Product(s): Lomitapide

              Therapeutic Area: Cardiology/Vascular Diseases Product Name: Lojuxta

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Amryt Pharma

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement October 19, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY